#cabaletta bio Tech News.
1 story in the last 7 days
The latest cabaletta bio news, distilled by AI into sharp ~100-word summaries. ByteBrief tracks cabaletta bio across dozens of tech sources and brings you only what matters, updated hourly. Tap any story for the full brief, or open the original source.
TechYahoo Financeabout 5 hours ago
Cabaletta Bio Eyes Rese-Cel Launch for Autoimmune DiseasesCabaletta Bio delivered positive clinical data from the first four patients in the lowest dose cohort of PC-free rese-cel, an autologous CAR T therapy for autoimmune diseases. 50% of patients showed drug-free responses for six months. The company signed a long-term commercial supply agreement and plans to advance rese-cel toward BLA submission for a commercial launch.
Summaries by ByteBrief